Abstract
A multi-center, open trial was conducted to determine the maximal tolerable dose of carboplatin in combination with conventional doses of both etoposide and an anthracycline for the treatment of previously untreated small cell lung cancer (SCLC) patients. Ninety-five patients [48 with limited disease (LD) and 47 with extensive disease (ED)¦ received a total of 376 courses of treatment. Carboplatin was given on day 1 at a dose of 250 mg m−2 in 60 courses, 300 mg m−2 in 69, 330 mg m−2 in 236 and 350 mg m-2 in 11, with 120 mg m−2 etoposide on days 1, 3 and 5 and either 40 mg m-2 adriamycin or 60 mg m−2 epirubicin on day 1. Epirubicin was not administered before carboplatin reached the dose of 330 mg m−2. Courses were repeated every 3 weeks. The main toxicity was hematological. The first course of therapy induced a dose-dependent decrease of leucocyte, neutrophil and platelet counts: all patients, except one, who received 350 mg m−2 carboplatin had a neutropenia below 200 μ−1 and a thrombopenia below 100,000 μl−1. Three patients died of septicemia. Other toxicities were well tolerated. After three courses, patients were re-staged by performing a mandatory fiberoptic bronchoscopy and a thoracic computed axial tomography (CAT). The overall objective response rate for 86 evaluable patients was 91% (98% for LD) with 21% complete remissions (30% for LD). All 23 hepatic and six brain sites, evaluable after chemotherapy alone, responded. This new combination, in which the recommended dose of carboplatin is 330 mg m−2, should be evaluated in a prospective study for SCLC.
Similar content being viewed by others
References
Smith I E, Harland S J, Robinson B A,et al.: Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer.Cancer Treat Rep 69, 43 (1985).
Jacobs R H. Bitran J D, Deutsch M,et al.: Phase II study of carboplatin in previously untreated patients with metastatic small cell lung carcinoma.Cancer Treat Rep 71, 311 (1987).
Calvert A H, Harland S J, Newell D R,et al.: Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.Cancer Chemother Pharmac 9, 140 (1982).
Koeller J M, Earhart R H, Davis R E,et al.: Phase I trial of carboplatin (NSC 241240) by bolus intravenous injection.Proc Am Ass Cancer Res 24, 162 (1983).
Joss R A, Kaplan S, Goldhirsch A,et al.: A phase I trial of cis-diammine-l,l-cyclobutane dicarboxylate platinum II (carboplatin, CBDCA, JM-8) with a single dose every five week-schedule.Invest New Drugs 2, 297 (1984).
O’Dwyer P J, Leyland-Jones B, Alonso M T,et al.: Drug therapy. Etoposide (VP-16-213). Current status of an active anticancer drug.New Engl J Med 312, 692 (1985).
Einhorn L H: Initial therapy with cisplatin plus VP-16 in small cell lung cancer.Semin Oncol 13, 5 (1986).
Smith I E. Evans B D, Gore M E,et al.: Carboplatin (paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer.J clin Oncol 5. 185 (1987).
Broder L E, Cohen M H, Selawry O S: Treatment of bronchogenic carcinoma. II. Small cell.Cancer Treat Rev 4, 219 (1977).
Kolaric K, Eckhardt S, Jassem J,et al.: Phase II study of epirubicin (E) in previously untreated patients (pts) with extensive small cell lung cancer (SCLC).Lung Cancer 4, A109 (1988).
Torti F M, Bristow M R, Lum B L, Carter S K, Howes A E, Aston D A, Brown B W, Hannigan J F, Meyers F J, Mitchell E P, Billingham M E: Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy.Cancer Res 46, 3722 (1986).
Van Hoff D, Kuhn J, Clark G M: Design and conduct of phase 1 trials, in Buyse M E, Staquet M J, Sylvester R J (eds):Cancer Clinical Trials. Methods and Practice, pp. 210–220. Oxford University Press, Oxford (1984).
Smith I E, Perren T, Yarhold J,et al.: Carboplatin (C), VP16 (V), and ifosfamide (I) intensive chemotherapy (CT) for small cell lung carcinoma (SCLC). A phase II study.Lung Cancer 4, A104 (1988).
De Vita V T: Dose-response is alive and well.J clin Oncol 4, 1157 (1986).
Humblet Y. Symann M, Bosly A,et al.: Late intensification chemotherapy with autologous bone marrow transplantation in selected small cell carcinoma of the lung: a randomized study.J clin Oncol 5, 1864 (1987).
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Humblet, Y., Weynants, P., Bosly, A. et al. Carboplatin in association with etoposide and either adriamycin or epirubicin for untreated small cell lung cancer: A dose escalation study of carboplatin. Med. Oncol. & Tumor Pharmacother. 6, 207–212 (1989). https://doi.org/10.1007/BF02985192
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02985192